{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T04:38:26Z","timestamp":1795063106857,"version":"4.10.2"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1001\/jamaophthalmol.2018.2466","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T12:33:40Z","timestamp":1530189220000},"page":"981","source":"Crossref","is-referenced-by-count":128,"title":["Survival Rates in Patients After Treatment for Metastasis From Uveal Melanoma"],"prefix":"10.1001","volume":"136","author":[{"given":"Anne Marie","family":"Lane","sequence":"first","affiliation":[{"name":"Ocular Melanoma Center, Retina Service, Massachusetts Eye and Ear Infirmary, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana K.","family":"Kim","sequence":"additional","affiliation":[{"name":"Ocular Melanoma Center, Retina Service, Massachusetts Eye and Ear Infirmary, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos S.","family":"Gragoudas","sequence":"additional","affiliation":[{"name":"Ocular Melanoma Center, Retina Service, Massachusetts Eye and Ear Infirmary, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"eoi180048r1","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1001\/archopht.120.12.1665","article-title":"Evidence-based estimates of outcome in patients irradiated for intraocular melanoma.","volume":"120","author":"Gragoudas","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"eoi180048r2","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma.","volume":"44","author":"Kujala","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"eoi180048r3","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1167\/iovs.03-0081","article-title":"Uveal melanoma survival in Sweden from 1960 to 1998.","volume":"44","author":"Bergman","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"eoi180048r4","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","article-title":"Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma.","volume":"119","author":"Onken","year":"2012","journal-title":"Ophthalmology"},{"key":"eoi180048r5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/978-1-62703-727-3","article-title":"A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile.","volume":"1102","author":"Harbour","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"7","key":"eoi180048r6","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1001\/jamaophthalmol.2016.0913","article-title":"Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma.","volume":"134","author":"Walter","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"eoi180048r7","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1200\/JCO.2004.08.194","article-title":"Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23.","volume":"22","author":"Diener-West","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"eoi180048r8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0161-6420(91)32285-1","article-title":"Survival of patients with metastases from uveal melanoma.","volume":"98","author":"Gragoudas","year":"1991","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi180048r9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ajo.2011.03.004","article-title":"Surveillance testing for metastasis from primary uveal melanoma and effect on patient survival.","volume":"152","author":"Augsburger","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"eoi180048r10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ajo.2009.01.023","article-title":"Effectiveness of treatments for metastatic uveal melanoma.","volume":"148","author":"Augsburger","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"eoi180048r11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","article-title":"Metastatic disease from uveal melanoma: treatment options and future prospects.","volume":"101","author":"Carvajal","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"eoi180048r12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/00000421-199812000-00008","article-title":"Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials.","volume":"21","author":"Flaherty","year":"1998","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"eoi180048r13","first-page":"201","article-title":"BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy.","volume":"16","author":"Nathan","year":"1997","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"eoi180048r14","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0959-8049(03)00132-1","article-title":"Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.","volume":"39","author":"Kivel\u00e4","year":"2003","journal-title":"Eur J Cancer"},{"issue":"3","key":"eoi180048r15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/01.cmr.0000129377.22141.ea","article-title":"Phase I\/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver.","volume":"14","author":"Agarwala","year":"2004","journal-title":"Melanoma Res"},{"issue":"3","key":"eoi180048r16","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/annonc\/mdt585","article-title":"Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.","volume":"25","author":"Leyvraz","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"eoi180048r17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/COC.0b013e3181d2ed67","article-title":"A pilot study of bevacizumab and interferon-a2b in ocular melanoma.","volume":"34","author":"Guenterberg","year":"2011","journal-title":"Am J Clin Oncol"},{"issue":"23","key":"eoi180048r18","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1001\/jama.2014.6096","article-title":"Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.","volume":"311","author":"Carvajal","year":"2014","journal-title":"JAMA"},{"issue":"11","key":"eoi180048r19","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2217\/fon-2015-0075","article-title":"Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives.","volume":"12","author":"Komatsubara","year":"2016","journal-title":"Future Oncol"},{"issue":"3","key":"eoi180048r20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/CMR.0000000000000242","article-title":"The use of pembrolizumab for the treatment of metastatic uveal melanoma.","volume":"26","author":"Kottschade","year":"2016","journal-title":"Melanoma Res"},{"issue":"21","key":"eoi180048r21","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/cncr.30258","article-title":"Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.","volume":"122","author":"Algazi","year":"2016","journal-title":"Cancer"},{"issue":"20","key":"eoi180048r22","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1002\/cncr.28282","article-title":"Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.","volume":"119","author":"Luke","year":"2013","journal-title":"Cancer"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2686116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T12:31:56Z","timestamp":1536841916000},"score":1,"resource":{"primary":{"URL":"http:\/\/archopht.jamanetwork.com\/article.aspx?doi=10.1001\/jamaophthalmol.2018.2466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.2466","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}